AIM ImmunoTech announces that it will not proceed with an offering pursuant to its Registration Statement on Form S-1 until after it files its Annual Report on Form 10-K for the fiscal year ended December 31, 2024

Rhea-AI Summary

AIM ImmunoTech (NYSE American: AIM) has announced it will postpone its planned offering under Registration Statement Form S-1. The company will not proceed with the offering until after filing its Annual Report on Form 10-K for the fiscal year ended December 31, 2024.

Positive

• None.

Negative

• Delayed S-1 offering indicates potential delay in raising capital
• Postponement of offering may impact company's near-term funding plans

OCALA, Fla., Feb. 11, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it will not proceed with an offering pursuant to its Registration Statement on Form S-1 until after it files its Annual Report on Form 10-K for the fiscal year ended December 31, 2024.

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen^® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.

Cautionary Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “continue,” “believe,” “potential,” “upcoming” and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. No assurance can be given as to whether the Company will proceed with an offering. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.

FAQ

Why did AIM ImmunoTech delay its Form S-1 offering in February 2025?

AIM ImmunoTech delayed its Form S-1 offering until after filing its Annual Report on Form 10-K for the fiscal year ended December 31, 2024.

When will AIM ImmunoTech proceed with its planned offering?

AIM ImmunoTech will proceed with the offering after filing its Annual Report on Form 10-K for the fiscal year ended December 31, 2024.

What is the impact of AIM's delayed S-1 offering on its financing plans?

The delayed S-1 offering suggests a postponement in AIM's capital raising activities until after the company files its 2024 annual report.

What regulatory filings must AIM complete before proceeding with its offering?

AIM must complete and file its Annual Report on Form 10-K for fiscal year 2024 before proceeding with the Form S-1 offering.